PD-L1+ neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab.
Cristinziano L, Modestino L, Capone M, Madonna G, Mallardo D, Giannarelli D, D'Angelo G, Ferrara AL, Loffredo S, Varricchi G, Vanella V, Festino L, Ascierto PA, Galdiero MR.
Cristinziano L, et al. Among authors: loffredo s.
Front Immunol. 2022 Aug 9;13:962669. doi: 10.3389/fimmu.2022.962669. eCollection 2022.
Front Immunol. 2022.
PMID: 36016960
Free PMC article.